Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$236.97 USD

236.97
597,597

-1.09 (-0.46%)

Updated Oct 3, 2024 03:59 PM ET

After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track

ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.

    DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

    DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.

      VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2

      VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.

        IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up

        IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

          Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues

          Hill-Rom Holdings (HRC) rides high on international growth and product innovation.

            Company News For July 31, 2017

            Companies in the news are: EXPE,MRK,ALGN,MAT

              NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View

              NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.

                Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2

                Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.

                  AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?

                  AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.

                    Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1

                    Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.

                      GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates

                      Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).

                        Align Technology (ALGN) Beats on Q2 Earnings and Revenues

                        Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.

                          QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View

                          QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.

                            Merit Medical Systems (MMSI) Worth a Look: Stock Gains 7.7%

                            Merit Medical Systems, Inc. (MMSI) shares rose almost 8% in the last trading session.

                              McKesson (MCK) Misses Earnings Estimates in Q1, Raises View

                              McKesson's (MCK) performance was muted in the first quarter owing to branded to generic conversions and competition in its pharmacy business.

                                Integra LifeSciences (IART) Q2 Earnings Meet, Revenues Miss

                                Integra LifeSciences' (IART) solid performance in the Orthopedics and Tissue Technologies was the key highlight of the second quarter.

                                  CONMED (CNMD) Earnings Meet, Revenues Beat Estimates in Q2

                                  CONMED's (CNMD) strong global performance was a key highlight in the second quarter of 2017.

                                    LabCorp (LH) Beats on Q2 Earnings and Sales, Guidance Up

                                    LabCorp's (LH) dull Covance Drug Development performance is offset by solid growth in Diagnostics. Increased guidance raises hope.

                                      Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

                                      The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

                                        Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised

                                        Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.

                                          Should You Buy Align Technology (ALGN) Ahead of Earnings?

                                          Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

                                            Express Scripts (ESRX) Earnings Top in Q2, FY17 View Up

                                            Express Scripts (ESRX) perform well in the second quarter on the back of operational cost improvement backed by focus on home delivery and specialty services.

                                              What to Expect from International Paper (IP) in Q2 Earnings?

                                              Fluctuations in actual equity market returns, changes in general interest rates are likely to hurt International Paper (IP) in Q2 earnings.

                                                VASCO (VDSI) to Report Q2 Earnings: What's in the Offing?

                                                Vasco's (VDSI) focus on generating high operating margins, backed by continuous investments and a shift in the product mix with higher gross-margin products, is likely to boost its Q2 earnings.

                                                  PetMed Express (PETS) Tops Earnings, Revenue Estimates in Q1

                                                  PetMed (PETS) initiated fiscal 2018 with better-than-expected results in the first quarter, beating both earnings and revenues.